After decades of patient frustration, clinical confusion, and a name that never quite fit, polycystic ovary syndrome has officially been renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS) — and the science behind that decision is long overdue.

In this episode of The Shot, Tara breaks down the landmark May 2026 Lancet global consensus that drove the rename, why the old "polycystic" framing was scientifically inaccurate and clinically harmful, and what the new name actually tells us about what's happening in the body. She also covers what hasn't changed — including the current diagnostic criteria from the 2023 International Evidence-Based Guideline — and why this shift matters far beyond terminology.

Whether you have this diagnosis, treat patients who do, or just want to understand why words in medicine matter, this one's for you.

References

1. Teede HJ et al. Polyendocrine Metabolic Ovarian Syndrome, the New Name for Polycystic Ovary Syndrome: A Multistep Global Consensus Process. Lancet. 2026. doi:10.1016/S0140-6736(26)00717-8
2. Teede HJ et al. Recommendations From the 2023 International Evidence-Based Guideline. Hum Reprod. 2023;38(9):1655–1679. doi:10.1093/humrep/dead156
3. Teede HJ et al. 2023 IEBG Recommendations. J Clin Endocrinol Metab. 2023;108(10):2447–2469. doi:10.1210/clinem/dgad463
4. Peña AS, Witchel SF. Update on Diagnosis of PCOS During Adolescence. Fertil Steril. 2025. doi:10.1016/j.fertnstert.2025.09.006

New episodes every Monday → Hit that subscribe button! 🔔

⭐️ Rate and Review

🍸 Cocktail recipes drop on socials every weekend before the episode airs 🍹

If you love the podcast, please join our 💳 Patreon to support our continued success!

If you don't want to commit to a monthly contribution, you can always donate on ☕️Buy Me a Coffee

🎶 Music Credits: Music by Vlad Krotov, Sound Effect by Akiva Vita For updates visit our 💻 Website